RxDoctor Payments Data

Aphie Amams

Psychiatric/Mental Health · Orange, NJNPI 1497398861

Payments from drug & device makers

$2,517in general payments, 2019–2025

Across 124 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • AbbVie$516
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$255
  • Otsuka America Pharmaceutical, Inc.$188
  • Vanda Pharmaceuticals Inc.$151
  • Johnson & Johnson$96
  • plus $275 from 7 others

What the payments were for

  • Food & beverage$2,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,517 in reported general payments places this provider in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$28,526
Medicare patients
77
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate29$75,548
Risperdal ConstaRisperidone Microspheres21$27,011
Risperidone OdtRisperidone30$6,067
Lurasidone Hcl60$5,813
Varenicline Tartrate15$4,787
Aripiprazole111$4,641
Clonazepam343$2,744
Quetiapine Fumarate256$2,483
Quetiapine Fumarate ErQuetiapine Fumarate38$2,255
Divalproex Sodium113$1,741
Bupropion XlBupropion Hcl127$1,637
Duloxetine Hcl93$1,633
Risperidone208$1,501
Paliperidone ErPaliperidone14$1,283
Zolpidem Tartrate254$1,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$96$102,55950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →